Vivos Therapeutics reports Q2 2025 revenue $3.8M, operating loss $4.9M; acquired Sleep Center of Nevada

Vivos Therapeutics, Inc.

2025-Q2 EPS reported -$1.00 revenue$6,835,000

Q2 2025 revenue $3.8M vs $4.1M YoY; gross margin fell to 55% from 65%.
Operating loss widened to $4.9M from $1.9M; expenses up 52% on acquisition-related costs.
Cash at June 30, 2025 was $4.4M, down from $6.2M at December 31, 2024.
Acquired Sleep Center of Nevada on June 10; generated ~$500k diagnostic revenue in 20 days with demand exceeding capacity.
Entered management agreement with MISleep Solutions for Michigan center; opening expected October 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.